Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Xyphos Biosciences
Biotech
Astellas stops development of early-stage lymphoma CAR-T
Astellas has called it quits on the development of a CAR-T asset in lymphoma. The therapy leveraged technology from Astellas' subsidiary Xyphos.
Fraiser Kansteiner
Jan 9, 2025 6:49am
Astellas hops into Poseida's car for $50M cell therapy collab
May 1, 2024 12:49pm
Astellas puts the cork back in $350M Xork deal with Cartesian
Mar 14, 2024 10:41am
Astellas bets more than $800M on Kelonia's delivery tech
Feb 15, 2024 6:30pm
